Table 2.
Variables association to MMT dosing in cohort 2
| Gender (n = 90) | P‐value | [E2] (pg/ml; n = 89) | P‐value | [P4] (pg/ml; n = 87) | P‐value | ||||
|---|---|---|---|---|---|---|---|---|---|
| Male (n = 66) | Female (n = 24) | ≤20 (n = 45) | >20 (n = 44) | <0.4 (n = 45) | ≥0.4 (n = 42) | ||||
| pMax (avg.( S.D.)) | 80.98 (31.89) | 112.71 (57.54) | 0.016* | 82.67 (43.15) | 96.36 (41.45) | 0.1305 | 86.56 (39.57) | 92.62 (46.71) | 0.5144 |
| SS (avg.( S.D.)) | 48.98 (34.46) | 90.39 (60.93) | 0.0038** | 54.14 (47.33) | 66.03 (46.01) | 0.2329 | 62.04 (43.99) | 58.89 (50.17) | 0.7556 |
| Max (avg.(S.D.)) | 82.20 (31.78) | 122.50 (61.49) | 0.0048** | 83.56 (43.09) | 102.6 (46.11) | 0.0472* | 89.56 (44.16) | 96.90 (47.72) | 0.4576 |
pMax, Maximal MMT dose before enter this trial; SS, steady‐state MMT dose in this trial; Max, Maximal MMT dose during this trial; avg, average; S.D.: standard deviation; [E2]: 17β‐oestradiol; [P4]: pregn‐4‐ene‐3,20‐dione (progesterone). *P < 0.05; **P < 0.01.